Show simple item record

dc.contributor.authorDreno, B
dc.contributor.authorAscierto, PA
dc.contributor.authorAtkinson, V
dc.contributor.authorLiszkay, G
dc.contributor.authorMaio, M
dc.contributor.authorMandala, M
dc.contributor.authorDemidov, L
dc.contributor.authorStroyakovskiy, D
dc.contributor.authorThomas, L
dc.contributor.authorde la Cruz-Merino, L
dc.contributor.authorDutriaux, C
dc.contributor.authorGarbe, C
dc.contributor.authorBartley, K
dc.contributor.authorKaragiannis, T
dc.contributor.authorChang, I
dc.contributor.authorRooney, I
dc.contributor.authorKoralek, DO
dc.contributor.authorLarkin, J
dc.contributor.authorMcArthur, GA
dc.contributor.authorRibas, A
dc.date.accessioned2020-12-18T04:02:26Z
dc.date.available2020-12-18T04:02:26Z
dc.date.issued2018-03-20
dc.identifierpii: bjc2017488
dc.identifier.citationDreno, B., Ascierto, P. A., Atkinson, V., Liszkay, G., Maio, M., Mandala, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Dutriaux, C., Garbe, C., Bartley, K., Karagiannis, T., Chang, I., Rooney, I., Koralek, D. O., Larkin, J., McArthur, G. A. & Ribas, A. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma. BRITISH JOURNAL OF CANCER, 118 (6), pp.777-784. https://doi.org/10.1038/bjc.2017.488.
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/11343/256024
dc.description.abstractBACKGROUND: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. METHODS: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and ⩾1 time point thereafter constituted the analysis population. Change from baseline ⩾10 points was considered clinically meaningful. RESULTS: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains were also comparable between arms. A transient deterioration in role function in cycle 1 day 15 (C1D15; -14.7 points) in the P+V arm and improvement in insomnia in the C+V arm at C2D15 (-12.4 points) was observed. Among patients who experienced a ⩾10-point change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%) and pain (7%), all favouring C+V. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment. CONCLUSIONS: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with C+V maintained HRQOL compared with P+V, with superior efficacy.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleHealth-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma
dc.typeJournal Article
dc.identifier.doi10.1038/bjc.2017.488
melbourne.affiliation.departmentMelbourne Medical School
melbourne.source.titleBritish Journal of Cancer
melbourne.source.volume118
melbourne.source.issue6
melbourne.source.pages777-784
dc.rights.licenseCC BY
melbourne.elementsid1306147
melbourne.contributor.authorMcArthur, Grant
dc.identifier.eissn1532-1827
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record